Syngene Q2 FY27 Revenue Up 13% Sequentially, EBITDA Margin Improves

Syngene International reported a 13% sequential revenue growth in Q2 FY27, reaching ₹833 Crore, with Operating EBITDA margin improving by 6 percentage points to 18%. PAT before exceptional items was ₹381 Crore. For H1 FY27, revenue stood at ₹1,569 Crore, with Operating EBITDA at ₹238 Crore and a margin of 15%. The company highlighted progress in its CDMO business and customer engagement. Key developments include strengthening its Integrated Drug Discovery (IDD) offering under unified leadership and signing its first manufacturing agreement for the Bayview biologics facility in the U.S., with process development starting in India and manufacturing in the U.S. next fiscal year. The company also secured additional manufacturing contracts for its Bengaluru biologics facility.